Saturday, October 31, 2026

NetEase Stock Bullish By 3% At Session Start Today

ViaNews Editorial Team

December 29, 2020

NetEase Stock Bullish By 3% At Session Start Today

Shares of NetEase jumped 3.12% to $93.97 at 09:40 EST on Tuesday, after two consecutive sessions in a row of gains. NASDAQ Composite is jumping 0.74% to $12,899.42, after two sequential sessions in a row of gains. This seems, up to now, a somewhat positive trend trading session today.

NetEase's last close was $92.66, 10.17% under its 52-week high of $103.53.

NetEase's Sales

NetEase's sales growth is 34.7% for the current quarter and 37.6% for the next.

Volatility

NetEase's last day, last week, and last month's average volatility was a positive 0.09%, a positive 0.40%, and a negative 0.24%, respectively.

NetEase's last day, last week, and last month's high and low average amplitude percentage was 2.25%, 2.67%, and 2.64%, respectively.

NetEase's Stock Yearly Top and Bottom Value

NetEase's stock is valued at $93.97 at 09:40 EST, under its 52-week high of $103.53 and way higher than its 52-week low of $53.17.

NetEase's Moving Average

NetEase's worth is higher than its 50-day moving average of $89.96 and above its 200-day moving average of $91.04.

Previous days news about NetEase

NetEase cloud music concert by tfboys breaks guinness world records for most viewed paid concert. According to Business Insider on Sun Dec 27, "For the TFBOYS concert, NetEase Cloud Music used technologies including mixed reality (MR), image overlay and augmented reality (AR) to give the event a more realistic quality when compared to traditional online concerts. ", "SOURCE NetEase Cloud Music"

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com